These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31327255)

  • 1. First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs).
    Merkul E; Sijbrandi NJ; Muns JA; Aydin I; Adamzek K; Houthoff HJ; Nijmeijer B; Van Dongen GAMS
    Expert Opin Drug Deliv; 2019 Aug; 16(8):783-793. PubMed ID: 31327255
    [No Abstract]   [Full Text] [Related]  

  • 2. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
    Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
    Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with
    Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS
    J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the Pt
    Merkul E; Muns JA; Sijbrandi NJ; Houthoff HJ; Nijmeijer B; van Rheenen G; Reedijk J; van Dongen GAMS
    Angew Chem Int Ed Engl; 2021 Feb; 60(6):3008-3015. PubMed ID: 33185916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Phosphopantetheinyl Transferases.
    Grünewald J; Klock HE; Cellitti SE; Bursulaya B; McMullan D; Jones DH; Chiu HP; Wang X; Patterson P; Zhou H; Vance J; Nigoghossian E; Tong H; Daniel D; Mallet W; Ou W; Uno T; Brock A; Lesley SA; Geierstanger BH
    Bioconjug Chem; 2015 Dec; 26(12):2554-62. PubMed ID: 26588668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates.
    Huang R; Sheng Y; Wei D; Lu W; Xu Z; Chen H; Jiang B
    Bioorg Med Chem; 2020 Dec; 28(23):115793. PubMed ID: 33039798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
    Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
    J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate.
    Mohamed Amar IA; Huvelle S; Douez E; Letast S; Henrion S; Viaud-Massuard MC; Aubrey N; Allard-Vannier E; Joubert N; Denevault-Sabourin C
    Eur J Med Chem; 2022 Feb; 229():114063. PubMed ID: 34974337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.
    Wei C; Zhang G; Clark T; Barletta F; Tumey LN; Rago B; Hansel S; Han X
    Anal Chem; 2016 May; 88(9):4979-86. PubMed ID: 27075639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
    Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
    Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
    Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
    MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG.
    Shao S; Tsai MH; Lu J; Yu T; Jin J; Xiao D; Jiang H; Han M; Wang M; Wang J
    Bioorg Med Chem Lett; 2018 May; 28(8):1363-1370. PubMed ID: 29559276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates.
    Mendelsohn BA; Barnscher SD; Snyder JT; An Z; Dodd JM; Dugal-Tessier J
    Bioconjug Chem; 2017 Feb; 28(2):371-381. PubMed ID: 28060485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.
    Matsuda Y; Malinao MC; Robles V; Song J; Yamada K; Mendelsohn BA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():121981. PubMed ID: 32036254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency.
    Dovgan I; Ehkirch A; Lehot V; Kuhn I; Koniev O; Kolodych S; Hentz A; Ripoll M; Ursuegui S; Nothisen M; Cianférani S; Wagner A
    Sci Rep; 2020 May; 10(1):7691. PubMed ID: 32376903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates.
    Levengood MR; Zhang X; Hunter JH; Emmerton KK; Miyamoto JB; Lewis TS; Senter PD
    Angew Chem Int Ed Engl; 2017 Jan; 56(3):733-737. PubMed ID: 27966822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
    Akaiwa M; Dugal-Tessier J; Mendelsohn BA
    Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunoconjugates, drug-armed antibodies to fight against cancer].
    Haeuw JF; Caussanel V; Beck A
    Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.